AR112536A1 - Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos - Google Patents

Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos

Info

Publication number
AR112536A1
AR112536A1 ARP180102465A AR112536A1 AR 112536 A1 AR112536 A1 AR 112536A1 AR P180102465 A ARP180102465 A AR P180102465A AR 112536 A1 AR112536 A1 AR 112536A1
Authority
AR
Argentina
Prior art keywords
mixture
acid esters
formation
fatty acid
particles
Prior art date
Application number
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR112536A1 publication Critical patent/AR112536A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Reivindicación 1: Un método para reducir la formación de partículas subvisibles y visibles en un producto farmacológico, donde el método comprende: incluir por lo menos 100 mg/ml de un anticuerpo IgG en el producto farmacológico; e incluir una mezcla de ésteres de ácidos grasos de polioxietilén sorbitán en el producto farmacológico, en donde un contenido de ésteres de acido oleico en la mezcla es más de 98% de todos los esteres de ácidos grasos en la mezcla. Reivindicación 19: Una formulación que comprende: por lo menos 100 mg/ml de un anticuerpo IgG; y una mezcla de ésteres de ácidos grasos, en donde un contenido de esteres de ácido oleico en la mezcla es más de 98% de todos los ésteres de ácidos grasos en la mezcla. Reivindicación 22: La formulación de acuerdo con la reivindicación 19, en donde el anticuerpo IgG es un anticuerpo IgG4 y la formulación incluye proteína tipo fosfolipasa B 2.
ARP180102465 2017-09-19 2018-08-30 Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos AR112536A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560365P 2017-09-19 2017-09-19

Publications (1)

Publication Number Publication Date
AR112536A1 true AR112536A1 (es) 2019-11-06

Family

ID=63449670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102465 AR112536A1 (es) 2017-09-19 2018-08-30 Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos

Country Status (14)

Country Link
US (2) US12042538B2 (es)
EP (1) EP3684415A1 (es)
JP (2) JP7301043B2 (es)
KR (1) KR20200054980A (es)
CN (2) CN118416215A (es)
AR (1) AR112536A1 (es)
AU (2) AU2018336623B2 (es)
BR (1) BR112020005335A2 (es)
CA (1) CA3073935A1 (es)
IL (2) IL310113A (es)
MX (2) MX2020002850A (es)
SG (1) SG11202001564QA (es)
TW (2) TWI831747B (es)
WO (1) WO2019060062A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227126A1 (en) * 2019-05-03 2020-11-12 Lonza Ltd Determination of contaminants in cell-based products with flow imaging microscopy
WO2021228917A1 (en) * 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
AR123165A1 (es) * 2020-08-07 2022-11-02 Hoffmann La Roche Un método para la producción de composiciones protéicas
JP2024529107A (ja) 2021-08-13 2024-08-01 ビオテスト・アクチエンゲゼルシャフト フィブリノゲン組成物および調製方法
JP7367262B1 (ja) 2021-12-01 2023-10-23 中外製薬株式会社 抗体含有製剤の調製方法
TW202409060A (zh) 2022-05-02 2024-03-01 美商再生元醫藥公司 用於降低脂酶活性之方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU4986596A (en) 1995-02-16 1996-09-04 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69922740T2 (de) 1998-05-11 2005-12-08 Tosoh Corp., Shinnanyo Methode zur Trennung von Nucleinsäuren mittels Flüssigchromatographie
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
NZ534542A (en) 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
AU2003272368C1 (en) 2002-09-13 2009-07-23 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
WO2004087761A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
CA2552639C (en) 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US20060027454A1 (en) 2004-08-09 2006-02-09 Dinovo Augustine Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
RU2389552C2 (ru) 2004-10-21 2010-05-20 Джи-И Хелткер Байо-Сайенсиз АБ Способ очистки антител
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
WO2007064281A1 (en) 2005-12-02 2007-06-07 Ge Healthcare Bio-Sciences Ab Hydrophobic interaction chromatography
EP1998806A1 (en) 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US9766217B2 (en) 2006-09-08 2017-09-19 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
WO2008109721A1 (en) 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
EP2252952B1 (en) 2008-01-25 2019-03-13 Biogen MA Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
US8410928B2 (en) 2008-08-15 2013-04-02 Biogen Idec Ma Inc. Systems and methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
JP2012526121A (ja) 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
CN105861454B (zh) 2009-06-16 2020-03-03 建新公司 用于纯化重组aav载体的改进方法
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
BR112012020254A2 (pt) 2010-02-12 2016-05-03 Dsm Ip Assets Bv método para a purificação de anticorpos a partir de uma mistura de proteína e, unidade operacional única.
CN103096934A (zh) * 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
KR101841527B1 (ko) 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 개선된 고농도 항－ＴＮＦα 항체 액체 제형
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
JP6110786B2 (ja) 2011-03-28 2017-04-05 積水メディカル株式会社 Ｐｓａの測定方法及びその試薬
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
JP2014533700A (ja) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
DK2791176T3 (en) 2011-12-15 2018-10-15 Prestige Biopharma Pte Ltd PROCEDURE FOR CLEANING ANTIBODIES
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP3456352A1 (en) 2012-08-06 2019-03-20 Biogen MA Inc. Methods for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
AU2013361587A1 (en) 2012-12-20 2015-06-18 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
CN105377874A (zh) 2013-03-08 2016-03-02 建新公司 治疗性蛋白药物物质的整合连续制造
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR095615A1 (es) 2013-03-15 2015-10-28 Alder Biopharmaceuticals Inc Purificación de anticuerpos y monitoreo de pureza
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
SG11201508681QA (en) 2013-05-06 2015-11-27 Scholar Rock Inc Compositions and methods for growth factor modulation
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
CN105848746B (zh) 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
EP3060578A4 (en) 2013-10-25 2017-07-05 Medlmmune, LLC Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) * 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP3226899A4 (en) 2014-12-02 2018-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an il-6r antagonist
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN108602889A (zh) 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
MX2018007613A (es) 2015-12-22 2018-09-21 Regeneron Pharma Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
US10947262B2 (en) 2016-06-14 2021-03-16 Biogen Ma Inc. Hydrophobic interaction chromatography for purification of oligonucleotides
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
WO2019040671A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
US20210010055A1 (en) 2018-03-16 2021-01-14 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
US20210009632A1 (en) 2018-03-29 2021-01-14 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
KR20210021542A (ko) 2018-06-19 2021-02-26 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피를 사용하여 단백질을 정제하는 방법
CA3103817A1 (en) 2018-07-02 2020-01-09 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
WO2020023566A1 (en) 2018-07-25 2020-01-30 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
JP2021534151A (ja) 2018-08-15 2021-12-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 下流クロマトグラフィーにおける再酸化によるタンパク質断片化制御戦略
CN113301922A (zh) 2018-11-05 2021-08-24 百时美施贵宝公司 用于纯化聚乙二醇化蛋白的方法
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
US20220042954A1 (en) 2019-03-29 2022-02-10 Bristol-Myers Squibb Company Methods of measuring hydrophobicity of chromatographic resins
US20220267796A1 (en) 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods

Also Published As

Publication number Publication date
EP3684415A1 (en) 2020-07-29
AU2018336623B2 (en) 2024-05-09
BR112020005335A2 (pt) 2020-09-24
MX2020002850A (es) 2020-07-24
CN111201042B (zh) 2024-05-10
KR20200054980A (ko) 2020-05-20
TW201914615A (zh) 2019-04-16
US12042538B2 (en) 2024-07-23
MX2023014446A (es) 2023-12-15
SG11202001564QA (en) 2020-04-29
CN118416215A (zh) 2024-08-02
US20240335534A1 (en) 2024-10-10
AU2018336623A1 (en) 2020-03-12
AU2024205038A1 (en) 2024-08-15
US20190083618A1 (en) 2019-03-21
CN111201042A (zh) 2020-05-26
TWI831747B (zh) 2024-02-11
IL272954A (en) 2020-04-30
WO2019060062A1 (en) 2019-03-28
JP2020534260A (ja) 2020-11-26
CA3073935A1 (en) 2019-03-28
IL272954B1 (en) 2024-02-01
TW202417047A (zh) 2024-05-01
JP2023112046A (ja) 2023-08-10
IL310113A (en) 2024-03-01
JP7301043B2 (ja) 2023-06-30
IL272954B2 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
AR113749A1 (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
MY183807A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
CL2017001983A1 (es) Composiciones farmacéuticas para terapia combinada.
AR108074A1 (es) Composiciones de hormona esteroide en aceites de cadena media
AR097791A1 (es) Formulaciones de anticuerpos anti-pdl1
AR086074A1 (es) Composiciones y metodo para tratar enfermedades autoinmunes
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX2013009007A (es) Composiciones nutricionales altas en proteina y metodos para elaborar y utilizar las mismas.
CL2018003178A1 (es) Composición farmacéutica
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
PE20150190A1 (es) Formulacion farmaceutica
BR112019003175A2 (pt) métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica.
EA201691628A1 (ru) Состав для личной гигиены
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112022008172A2 (pt) Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
AR107195A1 (es) Composición lípida vegetal para promover el crecimiento del cabello, método para promover el crecimiento del cabello y uso de dichos lípidos vegetales
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
EA201890479A1 (ru) Гидрофобный гель на основе витамина е без продуктов силикона для местного применения
CO2023007955A2 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf